ConductScience.org, home

Library / Genes

CD22: CD22 molecule

1 protein, 153 patents, 13 drugs, 116 trials, 3,092 NIH grants and 8,823 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolCD22HGNC
NameCD22 moleculeHGNC
NCBI Gene ID933NCBI Gene
HGNC IDHGNC:1643HGNC
EnsemblENSG00000012124NCBI Gene
AliasesSIGLEC-2, SIGLEC2NCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P20273B-cell receptor CD228477Ensembl, GeneID, HGNCUniProt

Patents 153

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
US 12600781 B22026-04-14437P20273Espacenet
EP 4650780 A22025-11-19107P20273Espacenet
EP 4641201 A22025-10-2979P20273Espacenet
JP 2025147176 A2025-10-062269P20273Espacenet
JP 2025529142 A2025-09-04790P20273Espacenet
JP 2025529142 A2025-09-045771P20273Espacenet
US 12371689 B22025-07-295771P20273Espacenet
US 12371689 B22025-07-29790P20273Espacenet
US 12331117 B22025-06-17201P20273Espacenet
JP 2025517969 A2025-06-1279P20273Espacenet

Drugs 13

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
BECTUMOMABCHEMBL2108228CD22 otherOTHERChEMBL
BL22CHEMBL2109352CD22 binding agentBINDING AGENTChEMBL
EPRATUZUMABCHEMBL2108404CD22 inhibitorINHIBITORChEMBL
EPRATUZUMAB 90YCHEMBL2108357CD22 binding agentBINDING AGENTChEMBL
EPRATUZUMAB-CYS-TESIRINECHEMBL4297872B-cell receptor CD22 binding agentBINDING AGENTChEMBL
IMMURAIT-LL2CHEMBL2109508CD22 binding agentBINDING AGENTChEMBL
INOTUZUMABCHEMBL4297558CD22 binding agentBINDING AGENTChEMBL
INOTUZUMAB OZOGAMICINCHEMBL2108611CD22 binding agentBINDING AGENTChEMBL
MONO-DGA-RFB4CHEMBL2109354CD22 binding agentBINDING AGENTChEMBL
MOXETUMOMAB PASUDOTOXCHEMBL1743043CD22 binding agentBINDING AGENTChEMBL

Trials 116

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07476729INOTUZUMAB OZOGAMICINPHASE3ClinicalTrials.gov
NCT07443592INOTUZUMABClinicalTrials.gov
NCT07443488INOTUZUMAB OZOGAMICINPHASE2ClinicalTrials.gov
NCT07313852INOTUZUMABPHASE1/PHASE2ClinicalTrials.gov
NCT07238907INOTUZUMAB OZOGAMICINClinicalTrials.gov
NCT06985485INOTUZUMAB OZOGAMICINPHASE2ClinicalTrials.gov
NCT06863259INOTUZUMAB OZOGAMICINPHASE1ClinicalTrials.gov
NCT06861348INOTUZUMAB OZOGAMICINPHASE2ClinicalTrials.gov
NCT06554626INOTUZUMAB OZOGAMICINPHASE2ClinicalTrials.gov
NCT06533748INOTUZUMABPHASE2ClinicalTrials.gov

NIH grants 3092

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant1262,025NIH's project files
P30CA008748Cancer Center Support Grant842,025NIH's project files
ZIABC010301Development of Recombinant Toxins to Treat Hematologic Malignancies482,025NIH's project files
ZIABC011823Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies342,025NIH's project files
ZICSC009372Flow cytometric analysis of benign and malignant tumors322,025NIH's project files
P30CA021765Cancer Center Support Grant (CCSG)252,025NIH's project files
ZICBC011104Flow cytometric evaluation of biomarkers252,025NIH's project files
ZIABC010891Development of antibody engineering-based cancer therapies172,025NIH's project files
ZIABC008757Bio-Therapies for the Treatment of Cancer162,025NIH's project files
P01CA065493Off-the-Shelf Immune Effector Cells for Hematological Malignancies132,025NIH's project files

Papers 8823

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42813001PubTator, text miningPubMed
42807925PubTator, text miningPubMed
42802798PubTator, text miningPubMed
42789493PubTator, text miningPubMed
42779306PubTator, text miningPubMed
42765973PubTator, text miningPubMed
42755425PubTator, text miningPubMed
42716964PubTator, text miningPubMed
42702241PubTator, text miningPubMed
42690647PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license